09:24 AM EDT, 09/30/2024 (MT Newswires) -- GRI Bio ( GRI ) said Monday it has received a "decision to grant" notice from Japan's Patent Office for a patent application covering the use of natural killer T cell modulators to prevent and treat inflammatory diseases.

The patent covers claims, which include compositions and methods, for modulating type 2 and/or type 1 invariant natural killer T cells to prevent and treat the conditions, the company said.